CNBCさんのインスタグラム写真 - (CNBCInstagram)「Moderna shares soared after the company said its potential vaccine to prevent Covid-19 produced a “robust” immune response in all 45 patients in its early stage human trial, according to newly released peer-reviewed data.⁠ ⁠ In the trial, each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group. Participants received two doses of the potential vaccine.⁠ ⁠ After two vaccinations, the vaccine elicited a “robust” immune response in all participants in all dose cohorts, Moderna said. The company said the levels of neutralizing antibodies in patients in the high dose group were fourfold higher than in recovered Covid-19 patients. ⁠ ⁠ More details at the link in bio.⁠」7月16日 1時02分